You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC
|
|---|---|
| Published in |
Frontiers in oncology, July 2018
|
| DOI | 10.3389/fonc.2018.00262 |
| Pubmed ID | |
| Authors |
Corey J. Langer, Edward S. Kim, Eric C. Anderson, Robert M. Jotte, Manuel Modiano, Daniel E. Haggstrom, Matei P. Socoteanu, David A. Smith, Christopher Dakhil, Kartik Konduri, Tymara Berry, Teng J. Ong, Alexandra Sanford, Katayoun Amiri, Jonathan W. Goldman, Jared Weiss, on behalf of the ABOUND.70+ Investigators, Ajeet Gajra, Andrei Dobrescu, Bohdan E. Halibey, Corey Langer, Daniel Haggstrom, David A. Smith, Eric Anderson, Eugene H. Paschold, Haiying Cheng, Haythem Ali, Hossein Borghaei, Jared Weiss, Jawad Elias Francis, Ayla Ahmed Kessler, Jen C. Wang, Jonathan Wade Goldman, Jose E. Najera, Nadim F. Nimeh, Joseph Rosales, Kartik Konduri, Konstantin H. Dragnev, Leonardo Forero, Lynne A. Bui, Marc R. Matrana, Matei P. Socoteanu, Maurice Willis, Monika Joshi, Morton Coleman, Moses Sundar Raj, Navkiranjit Gill, Patricia M. Plezia, Manuel R. Modiano, R. Timothy Webb, Rita Axelrod, Robert Andrew Dichmann, Robert M. Jotte, Ronald P. Harris, Scott Anthony Sonnier, Vijay Patel, Shaker R. Dakhil, Tarek Mekhail, Thomas Hensing, Tony M. Samaha, Vicky Lee, Kimberly McGregor, William Eyre Lawler, William L. Skinner, William T. DeRosa |
| Abstract |
The phase 4 ABOUND.70+ trial assessed the safety and efficacy of nab-paclitaxel/carboplatin continuously or with a 1-week break between cycles in elderly patients with advanced non-small cell lung cancer (NSCLC). Patients ≥70 years with locally advanced/metastatic NSCLC were randomized 1:1 to first-line nab-paclitaxel days 1, 8, 15 plus carboplatin day 1 of a 21-day cycle (21d) or the same nab-paclitaxel/carboplatin regimen with a 1-week break between cycles (21d + break; 28d). The primary endpoint was the percentage of patients with grade ≥ 2 peripheral neuropathy (PN) or grade ≥ 3 myelosuppression. Other key endpoints included progression-free survival (PFS), overall survival (OS), and overall response rate (ORR). A total of 143 patients were randomized (71 to 21d, 72 to 21d + break). The percentage of patients with grade ≥ 2 PN or grade ≥ 3 myelosuppression was similar between the 21d and 21d + break arms (76.5 and 77.1%; P = 0.9258). Treatment exposure was lower in the 21d arm compared with the 21d + break arm. Median OS was 15.2 and 16.2 months [hazard ratio (HR) 0.72, 95% CI 0.44-1.19; P = 0.1966], median PFS was 3.6 and 7.0 months (HR 0.48, 95% CI 0.30-0.76; P < 0.0019), and ORR was 23.9 and 40.3% (risk ratio 1.68, 95% CI 1.02-2.78; P = 0.0376) in the 21d and 21d + break arms, respectively. In summary, the 1-week break between treatment cycles significantly improved PFS and ORR but did not significantly reduce the percentage of grade ≥ 2 PN or grade ≥ 3 myelosuppression. Overall, the findings support the results of prior subset analyses on the safety and efficacy of first-line nab-paclitaxel/carboplatin in elderly patients with advanced NSCLC. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 75% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 50% |
| Members of the public | 2 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 13 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 2 | 15% |
| Other | 1 | 8% |
| Lecturer | 1 | 8% |
| Student > Ph. D. Student | 1 | 8% |
| Student > Bachelor | 1 | 8% |
| Other | 2 | 15% |
| Unknown | 5 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 31% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 15% |
| Psychology | 1 | 8% |
| Nursing and Health Professions | 1 | 8% |
| Unknown | 5 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 February 2021.
All research outputs
#15,175,718
of 25,385,509 outputs
Outputs from Frontiers in oncology
#4,551
of 22,428 outputs
Outputs of similar age
#180,337
of 340,712 outputs
Outputs of similar age from Frontiers in oncology
#63
of 155 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,428 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 340,712 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 155 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.